Key Drivers
- Strong Profitability
- Weaker Liquidity
- High Intangibles
AIAI Summary
NBIX is evolving into a diversified specialty-pharma platform, but the investment case hinges on CRENESSITY and Soleno scaling quickly enough to reduce INGREZZA dependence before pricing pressure intensifies; consider accumulation only if INGREZZA volume remains strong and new-product growth sustains despite payer constraints.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Profitability
- •Weaker Liquidity
- •High Intangibles
NBIX remains profitable and cash-generative with sound leverage, but weakening liquidity and a large intangible-asset balance warrant caution despite moderately improved valuation multiples.
Price Behavior
Key Price Behavior Insights:
- •Sharp late selloff
- •Support under test
- •Weak momentum
NBIX is bearish over the last month, with a sharp drop to $146.23 testing $146 support; a hold could spark a rebound, while a break lower risks further downside.
Sharp four-session decline from $157.22 to $146.23
Sentiment & News
Key News Insights:
- •Ingrezza Exclusivity
- •Crenessity Growth
- •Mixed Ownership
Neurocrine's strong Ingrezza durability, accelerating Crenessity uptake, and broad pipeline support growth optimism, though valuation and mixed institutional activity warrant caution.
Commercial momentum is positive for Neurocrine, but valuation sensitivity may limit near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings